Stock Price Prediction

NVCT stock is currently trading at $6.715, recovering slightly after a sharp 43% drop due to disappointing Phase 1b trial results for NXP800. The bearish sentiment stems from safety concerns like thrombocytopenia and limited efficacy, though the company plans to adjust dosing and release further data in Q2 2025. Bulls may argue that FDA Fast Track and Orphan Drug Designations provide long-term potential, but near-term risks dominate.

NVCT stock is bearish, currently trading at $6.00 after a 44% drop due to disappointing Phase 1b trial results for NXP800, which showed limited efficacy and safety concerns like thrombocytopenia. The company's plan to increase dose intensity in future trials adds uncertainty, with no significant catalysts expected until Q2 2025. The sharp decline reflects weak investor confidence in the near term.